VisionCare Announces Presentations on Pivotal Trial Results at the American Academy of Ophthalmology Annual Meeting
Macular Degeneration Clinical Trial Outcomes Highlighted
in Scientific Sessions
SARATOGA, Calif., Oct. 11 /PRNewswire/ -- VisionCare Ophthalmic Technologies, Inc., a developer of advanced visual prosthetic devices for the treatment of age-related macular degeneration (AMD), announced today three presentations related to its pivotal trial of the Implantable Miniature Telescope (IMTTM by Dr. Isaac Lipshitz) are scheduled at the upcoming 109th Annual Meeting of the American Academy of Ophthalmology (AAO) in Chicago, IL from October 15 - 18, 2005 at McCormick Place convention center. One-year safety and efficacy results from the Phase II/III prospective, multicenter AMD clinical trial are scheduled for presentation as follows: -- Friday, October 14, 11:28 - 11:36 a.m., Implantable Miniature Telescope Trial: A Visual Prosthetic Device for End-Stage AMD -- 12-Month Results from the IMT002 Trial. Paul Sternberg, Jr., MD. Session: Retina Subspecialty Day, North Hall B1 -- Sunday, October 16, 10:15 - 10:30 a.m., Implantable Miniature Telescope. Stephen S. Lane, MD. Session: SPE 12 Vision Rehabilitation Program: Part I Technology and Techniques for Patients with Macular Degeneration, Room N135 -- Tuesday, October 18, 3:20 - 3:27 p.m., One-Year Phase II/III Results of a Visual Prosthetic Device for the Treatment of Vision Loss Due to Macular Degeneration. Henry L. Hudson, MD. Session: Retina Free Paper Session, Room S406a VisionCare also announced today that two-year follow-up, specified in the study protocol for long-term safety surveillance, is now complete. The trial is evaluating the safety and efficacy of the Company's telescope prosthetic device in individuals with moderate to profound bilateral central vision impairment associated with end-stage AMD. The trial enrolled over 200 patients at 28 leading medical universities and ophthalmic centers across the country. The telescope prosthetic device is designed to be a permanent solution for moderate to profound vision loss due to AMD. Smaller than a pea, the telescope is implanted in one eye in an outpatient surgical procedure. In the implanted eye, the device renders enlarged central vision images over a wide area of the retina to improve central vision, while the non-operated eye provides peripheral vision for mobility and orientation. About Macular Degeneration Macular degeneration is a disorder of the central retina, or macula, which is responsible for detailed vision that controls important functional visual activities like reading, recognizing faces, and watching television. According to the National Eye Institute over 1.7 million Americans over age 50 suffer mild to profound vision loss from advanced AMD, which culminates as end-stage AMD. Approximately half of the individuals living with advanced AMD are affected in both eyes. About VisionCare VisionCare Ophthalmic Technologies, Inc., headquartered in Saratoga, CA is a privately-held company focused on development, manufacturing, and marketing of visual prosthetic devices. The Implantable Miniature Telescope was invented by company founders, Isaac Lipshitz, M.D. and Yossi Gross. Information on VisionCare can be found at www.visioncareinc.net.
SOURCE VisionCare Ophthalmic Technologies, Inc.
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.